ReviewJournal of medical case reports2025
Primary hepatic neuroendocrine tumor with multiple intrahepatic metastases and concurrent hepatic angiomyolipoma: a case report and review of the literature.
Review in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPrimary hepatic neuroendocrine tumor is extremely rare, and hepatic angiomyolipoma is also a rare benign tumor of the liver with malignant biological behavior. The combination of primary hepatic neuroendocrine tumor and hepatic angiomyolipoma is exceptionally rare, and to date, there have been no reports in the literature. CASE PRESENTATION: In this report, we present the case of a 70-year-old elderly Han man living in Mainland China with multiple intrahepatic metastases from a primary hepatic neuroendocrine tumor complicated with hepatic angiomyolipoma. He was admitted to our hospital with complaints of "recurrent diarrhea and progressively worsening abdominal pain." After admission, further imaging studies disclosed lesions with mixed signal intensity in the S2 segment of the liver, highly suggestive of hepatic angiomyolipoma, in addition to a well-defined mass adjacent to the gallbladder in the S4 segment of the left hepatic lobe, the nature of which remains undetermined, along with multiple other foci of abnormal signal intensity. Percutaneous biopsy of the mass adjacent to the gallbladder in the S4 segment of the liver confirmed a diagnosis of neuroendocrine tumor, and the symptoms of diarrhea were considered to be related to the tumor. With subsequent positron emission tomography-computed tomography imaging ruling out metastatic sources, the patient subsequently underwent open abdominal surgery for resection of multiple liver masses and left hepatic lobectomy. The pathological results revealed a larger nodule in the left hepatic lobe consistent with hepatic vascular smooth muscle lipoma (S2 segment). In addition, smaller nodules in the left hepatic lobe, adjacent to the gallbladder in the S4 segment, and in the S6 segment were consistent with neuroendocrine tumors (grade 1). The symptoms of diarrhea improved after operation. Postoperatively, abdominal contrast-enhanced computed tomography examination showed no residual masses, and adjuvant therapy was not administered. Follow-up at 6 months with liver contrast-enhanced magnetic resonance imaging revealed no tumor recurrence.
conclusionIn the extremely rare case reported herein, concurrent primary hepatic neuroendocrine tumor and hepatic angiomyolipoma was confirmed by imaging and pathology, and diarrhea was confirmed to be related to primary hepatic neuroendocrine tumor after surgery. This case not only highlights the association between neuroendocrine tumors and metabolic symptoms but also sheds light on the diagnosis and treatment of unexplained metabolic symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.